

12<sup>th</sup> Asian

# BIOLOGICS AND BIOSIMILARS CONGRESS

August 20-21, 2018 Tokyo, Japan

## Institutional experiences in clinical evaluation of biosimilars

**Divya Chadha Manek**  
NIHR Clinical Research Network, UK

Uptake and acceptance of biosimilar medicines in the UK is accelerating and will continue to do so as the NHS (National Health Service) has recently introduced a new commissioning framework for biologic and biosimilar medicines. But there is still work to do to optimize the potential cost-saving benefits of biosimilar throughout the NHS. This presentation describes how unique challenges in the UK to the delivery of biosimilar clinical trials have been identified and overcome. It demonstrates how our biosimilar research delivery strategy was put into practice and will use case study examples and project outputs to illustrate the results. Finally, it will showcase the UK's ongoing campaign which continues to drive changes in attitudes, appetite and acceptance for biosimilars in the UK National Health Service.

### Biography

Divya Chadha Manek is the Head of Business Development (Commercial) for the National Institute for Health Research (NIHR) Clinical Research Network (CRN)-the clinical research delivery arm of the NHS. Her role is to establish new and maintain existing strategic relationships with global and UK life sciences companies. She also leads on ensuring that the clinical research network is abreast of new study delivery innovations to ensure that the organization is evolving to service life sciences industry requirements.

[divya.chadhamanek@nihr.ac.uk](mailto:divya.chadhamanek@nihr.ac.uk)